Quick Answer
Bolt Biotherapeutics, Inc. reported Earnings Per Share Diluted of $17.85 (loss) per share for the year ending 2025.
- Bolt Biotherapeutics, Inc. showed an increase of +46.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Bolt Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $0.63 (loss) per share | Q1 2022: $0.64 (loss) per share | Q2 2022: $0.61 (loss) per share | Q3 2022: $0.58 (loss) per share | Q1 2023: $0.45 (loss) per share | Q2 2023: $0.48 (loss) per share | Q3 2023: $0.43 (loss) per share | Q1 2024: $0.28 (loss) per share | Q2 2024: $11.12 (loss) per share | Q3 2024: $7.93 (loss) per share | Q1 2025: $0.29 (loss) per share | Q2 2025: $4.46 (loss) per share | Q3 2025: $3.72 (loss) per share.
- Over the full 5 years of available data (2021 to 2025), Bolt Biotherapeutics, Inc.'s Earnings Per Share Diluted has declined by 501.0%.
- Historical annual values: Fiscal year 2025: $17.85 (loss) per share | Fiscal year 2024: $33.06 (loss) per share | Fiscal year 2023: $1.83 (loss) per share | Fiscal year 2022: $2.36 (loss) per share | Fiscal year 2021: $2.97 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: